FILING ANALYSIS · THURSDAY, NOVEMBER 12
Yarrow Bioscience, Inc. YARW — 8-K: Results of Operations and Financial Condition
negative
The company completed an underwritten public offering, raising $172.5 million, which will be used to advance clinical development of YB-101, but this capital raise represents dilution for existing shareholders. The cash position is now $268.9 million, expected to fund operations into 2030.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →